REFERENCES
- Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002 ;16(18):2447–2454.
- van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009;4(5):e5647.
- Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971–979.
- Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14(10):1309–1316.
- Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucle-osides. AIDS. 2005;19(16)1 807–1818.
- Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants rand-omized to nelfinavir or efavirenz or both plus dual nucle-osides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr A 2007;45(5):508–514.
- Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleo-side and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109–1118.
- Moyle G, Fisher M, Sweet Study Group. Factors associ-ated with low limb fat in a cohort of zidovudine-treated subjects. Antiviral Ther 2007;12\(suppl 2):L28.
- McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combina-tion with lamivudine and stavudine: a 96-week randomized, controlled study. Clin Infect Dis. 2009;48(9):1323–1326.
- Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir diso-proxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47(1):74–78.
- Brown TT, Xu X, John M, et al. Fat distribution and longi-tudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther 2009;6:8.
- Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32(1):48–56.
- Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribu-tion in men with HIV infection. J Acquir Immune Defic Syndr 2005;40(2):121–131.
- World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 rev. http://www.who.int/hiv/pub/ary/adult2010/en/index.html.